In other tumor entities, the results of phase I (breast cancer, NCT 01837095) and phase II studies (pancreatic cancer, NCT 04177810) are still pending, but at present, CXCR4 inhibitors have not met the expectations of clinical efficacy [14]. This evidence concerns the gene CXCR4 and neoplasm.